Applied Therapeutics Announces Initiation of Registrational Phase 2/3 Study of AT-007 in SORD Deficiency
December 16, 2021 07:00 ET
|
Applied Therapeutics
NEW YORK, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated...
Applied Therapeutics to Present at the 14th International Congress of Inborn Errors of Metabolism
November 18, 2021 07:00 ET
|
Applied Therapeutics
NEW YORK, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated...
Applied Therapeutics Reports Third Quarter 2021 Financial Results
November 12, 2021 07:00 ET
|
Applied Therapeutics
Data from pilot trial of AT-007 in SORD deficiency expresses substantial and significant reduction in sorbitol Data from the ACTION-Galactosemia Kids study demonstrates statistically significant...
Applied Therapeutics Reports Biomarker Data from Pilot Trial of AT-007 in SORD Deficiency
October 25, 2021 07:00 ET
|
Applied Therapeutics
Substantial and significant reduction in sorbitol Company plans to initiate registrational trial by end of 2021 Company to host conference call and webcast today at 8:30 a.m. ET NEW YORK, Oct. 25,...
Applied Therapeutics Reports Additional Pediatric Biomarker Data from ACTION-Galactosemia Kids
October 18, 2021 07:00 ET
|
Applied Therapeutics
Substantial and statistically significant reduction in plasma galactitol of 40% with new weight-based dosing parameters Baseline galactitol levels clearly correlated with baseline clinical functional...
Applied Therapeutics Reports Initial Pediatric Biomarker Data from ACTION-Galactosemia Kids
September 09, 2021 07:00 ET
|
Applied Therapeutics
Substantial and statistically significant reduction in plasma galactitol Baseline analysis demonstrates clear relationship between plasma galactitol level and severity of disease in pediatric...
Applied Therapeutics Reports Second Quarter 2021 Financial Results
August 12, 2021 07:00 ET
|
Applied Therapeutics
NDA submission for AT-007 in Galactosemia expected in Q3 2021; commercial preparations ongoing Ended Q2 2021 with a strong balance sheet with $125.6 million in cash and cash equivalents and...
Applied Therapeutics Added to Russell Microcap® Index
June 28, 2021 07:00 ET
|
Applied Therapeutics
NEW YORK, June 28, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated...
Applied Therapeutics Announces Presentation of Data on the Prevalence of Diabetic Cardiomyopathy at the 81st Scientific Sessions of the 2021 Annual Meeting of the American Diabetes Association
June 25, 2021 12:05 ET
|
Applied Therapeutics
~1 in 5 people with diabetes or pre-diabetes have Diabetic Cardiomyopathy, a serious and progressive disease that limits the heart’s ability to function People with diabetes or pre-diabetes who have...
Applied Therapeutics to Present on Diabetic Cardiomyopathy and Prevalence of Disease at the 81st Scientific Sessions of the 2021 Annual Meeting of the American Diabetes Association
June 21, 2021 07:00 ET
|
Applied Therapeutics
NEW YORK, June 21, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated...